CRUCELL HOLLAND B.V.

ADAPT

Treatment of cells and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals for use in the manufacture of pharmaceuticals of genetic biochemicals;Genetic modified cells and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals all for medical and clinical use;Genetic modified cells and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals all for use in the manufacture of pharmaceuticals and for scientific and laboratory research;Scientific research; services in the medical and biochemical field, especially the examination and testing of genes, development, examination and testing of pharmaceutical and biochemical semi-finished products especially for use in medicines, the development, examination and testing of medicines, the development of test systems for genetically modified material for the preparation of pharmaceutical products and for research and diagnostic purposes;

CRUCELL

In the statement Column 1, lines 1 through 3 should be deleted, and in the Statement, Column 1, line 4 2333 Al Leiden, Netherlands should be deleted and Crucell Holland B.V., (Netherlands Corporation), P.O. Box 2048, 2301 CA Archimedesweg 4, Netherlands, should be inserted.;pharmaceuticals and pharmaceutical components in the field of genetic pharmacology;biochemicals for use in the field of genetic pharmacology, namely, genetic materials for the manufacture, research and development of gene and cell therapy products;scientific and medical research, consulting and technology licensing services in the field of genetic pharmacology;

CRUCELL

Pharmaceutical preparations in the field of pharmacology for the treatment of cancer, inherited diseases, auto-immune diseases and viral-related diseases;Biochemicals, namely, recombinant polypeptides for in vitro scientific or research use; monoclonal antibodies and fragments thereof for in vitro scientific or research use; biochemicals for use in the field of genetic pharmacology, namely, genetic materials for the manufacture, research and development of gene and cell therapy;Scientific and medical research, consulting and technology licensing services in the field of genetic pharmacology;The stippling is for shading purposes.;

CRUCELL

Pharmaceutical preparations for the treatment and prevention of infectious diseases; vaccines;Licensing of intellectual property in the field of genetic pharmacology;

HUMADE

Human monoclonal antibodies that are produced in human cell lines for medical diagnostic use; human monoclonal antibodies conjugated to proteins or fragments of other antibodies for clinical medical use; divalent human monoclonal antibodies for medical diagnostic use; human scFv or Fab antibodies for medical diagnostic use;Biochemicals, namely, human monoclonal antibodies that are produced in human cell lines for in vitro scientific or research use; human monoclonal antibodies conjugated to proteins or fragments of other antibodies for in vitro scientific or research use; divalent human monoclonal antibodies for in vitro scientific or research use; human scFv or Fab antibodies for in vitro scientific or research use;

MABACUS

The treatment of libraries of bacteriophages expressing at their surface a monoclonal antibody, and the treatment of bacterieophages isolated from such libraries;Libraries of bacteriophages expressing a monoclonal antibody at their surface, bacteriophages isolated from such libraries; human monoclonal antibodies to be used for research, human therapeutics or diagnostics; bacteria; media for culturing bacteriophages;Scientific research; medical and biochemical services, in particular the research and identification of bactefieophages; research, development and identification of monoclonal antibodies;

MABILITY

diagnostic bacteriophage reagents in the nature of monoclonal antibodies for clinical medical laboratory use; medical diagnostic reagents, namely, human monoclonal antibodies for human therapeutic and diagnostic use;bacteriophage reagents in the nature of monoclonal antibodies for scientific or medical research use; human monoclonal antibodies for scientific or medical research use;laboratory research in the field of human monoclonal antibodies; laboratory research in the field of human monoclonal antibodies, namely, research regarding antigen binding affinities and antibody biological activities; bacteriological research and testing in the field of human monoclonal antibodies; biochemical laboratory research and analysis services; research and identification of human monoclonal antibodies for others; chemical and medical research and development of monoclonal antibodies for others;

MABVANTAGE

laboratory research in the field of human monoclonal antibodies; laboratory research in the field of human monoclonal antibodies, namely, research regarding antigen binding affinities and antibody biological activities; bacteriological research and testing in the field of human monoclonal antibodies; biochemical laboratory research and analysis services research and identification of human monoclonal antibodies for others; chemical and medical research and development of monoclonal antibodies for others;

PER.C6

Treatment of cells, chemical solutions, DNA delivery vehicles, proteinaceaous molecules and nucleic acids for use in the preparation of pharmaceuticals and/or genetic biochemicals;Cells, cell-lines and culture media for the cultivation of cells, for medical or clinical use, pharmaceutical products, namely, viruses, viral vectors, therepeutic proteins and vaccines;PER.C SIX;Scientific services, namely, research in the medical and biochemical field, namely, the examination and testing of genes, pharmaceutical and biomedical semi-finished products, test systems for cells and cell-lines; culture media for cultivation of cells and cell-lines; genetically modified materials for the development of medicines, gene banks and diagnostic purposes, services for third parties for preparation and production of unfinished pharmaceutical products, cell line generation and cell banking;

PER.C6

Treatment of cells, chemical solutions, DNA delivery vehicles, proteinaceaous molecules and nucleic acids for use in the preparation of pharmaceuticals and/or genetic biochemicals;Cells, cell-lines and culture media for the cultivation of cells, for medical or clinical use, pharmaceutical products, namely, viruses, viral vectors, therapeutic proteins and vaccines;PER.C SIX;The applicant claims color as a feature of the mark, namely, ---, ---, ---.;Scientific services, namely, research in the medical and biochemical field, namely, the examination and testing of genes, phamaceutical and biomedical semi-finished products, test systems for cells and cell-lines; culture media for cultivation of cells and cell-lines; genetically modified materials for the development of medicines, gene banks and diagnostic purposes, services for third parties for preparation and production of unfinished pharmaceutical products, cell line generation and cell banking;

PER.CMAB

Diagnostic and therapeutic reagents in the nature of human monoclonal antibodies for clinical medical laboratory use; medical diagnostic and therapeutic regents in the nature of human monoclonal antibodies for use in the treatment of cancer targeting, chronic inflammation, pathogenic infections, vaccination in the field of human therapeutics;PER CMAB;Diagnostic reagents and therapeutic reagents in the nature of human monoclonal antibodies for scientific and research use in the field of human therapeutics;Laboratory research in the field of the isolation and purification of human monoclonal antibodies; laboratory research in the field of human monoclonal antibodies, namely research regarding the isolation and purification of human monoclonal antibodies; biological research and testing in the field of the isolation and purification of human monoclonal antibodies; scientific research; medical services and biochemical research regarding the production of human proteins in human cell lines and the importance of human post-translational modifications; chemical and medical research, synthesis and development of human monoclonal antibodies for others; biochemical research; laboratories and analysis for others;

PERCIVIA

Live cells and cell-lines for medical or clinical use; media (culture broth) for the cultivation of cells and cell-lines; genetically modified materials for the preparation of pharmaceutical products and for research purposes; pharmaceutical products, namely diagnostic and therapeutic proteins;Services in the medical and biomedical field; medical services;Scientific and pharmaceutical research; services in the medical and biochemical field, namely expressing proteins; development, examination and testing of pharmaceutical and biochemical semi-finished products for use in medicines; the development of test systems for the products named in class 5; licensing in the field of intellectual property;

PERCIVIA

Live cells and cell-lines for medical or clinical use; pharmaceutical products as bio-engineered component for therapeutic material, namely, therapeutic proteins for the prevention and treatment of viral, infectious and genetic diseases;Licensing of intellectual property;Scientific and pharmaceutical research; scientific research services in the medical and biochemical field, namely, expressing proteins; pharmaceutical research and development, namely, development, examination and testing of pharmaceutical and biochemical semi-finished products for use in medicines;